November 8, 2016
SEIKAGAKU CORPORATION(Securities Code: TSE 4548)

Seikagaku Announces Exclusive Distributorship Agreement inthe U.S. for VISCO-3™, A Three-Injection
Viscosupplement ProductSeikagaku Corporation (“Seikagaku”) (head office: Tokyo, Japan) today announced that it
has entered into an exclusive distributorship agreement in the United States for VISCO-3™,
a hyaluronic acid based viscosupplement product which requires three injections for thetreatment of knee osteoarthritis pain, with Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”)(head office: Warsaw, Indiana, U.S.A.).
As an aging population is growing in the U.S, expansion of the market for viscosupplement
products is expected to continue. The market supports products with different numbers ofinjections, which are used according to the diverse needs of physicians and patients.
Zimmer Biomet has sold Gel-One®, a single-injection viscosupplement productmanufactured by Seikagaku, in the U.S. since 2012. With the conclusion of this agreement,
Zimmer Biomet adds VISCO-3™ to its product line.
Seikagaku will have a line of products with three different numbers of injections, whole typeof injection product, after the introduction of VISCO-3™ in the U.S. market, in addition to®

®

the existing Gel-One single-injection treatment and SUPARTZ FX five-injection treatment.
In its role as the manufacturer of VISCO-3™, Seikagaku will continue to work to increase
the presence of its products in the U.S., a key region in the growth strategy, by supporting
the sales activities of the sales partner through the provision of academic information andmeasures to enhance the added value of products.
The impact of this matter on the consolidated financial results for the fiscal year ending
March 31, 2017 will be minor and has been taken into account in the revised forecast ofconsolidated financial results disclosed on November 8, 2016.
< About VISCO-3™, a three-injection viscosupplement product >VISCO-3™, an injectable treatment the active ingredient of which is hyaluronic acid, wasapproved by the U.S. Food and Drug Administration (FDA) in December 2015 as a medical
device indicated for knee osteoarthritis. It is a three-injection kit product for administering athree-dose treatment cycle (three doses given once weekly). Knee osteoarthritis is adisease characterized by the degeneration of articular cartilage and consequent swellingand pain. Injection of hyaluronic acid is a therapy used to curb the progress of symptoms.
1/2

< About Zimmer Biomet Holdings, Inc. >Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader
in musculoskeletal healthcare. Zimmer Biomet designs, manufactures and markets
orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma
products; office based technologies; spine, craniomaxillofacial and thoracic products;
dental implants; and related surgical products. In the field of viscosupplement products,
Zimmer Biomet is the sales partner in the U.S. for Gel-One®, Seikagaku’s single-injection
product.
< Cautionary Notes >This press release contains forward-looking statements regarding future management
strategies or performance forecasts. These statements are based on judgments derived
from information that is currently available to Seikagaku and are subject to risk anduncertainty. Actual results and developments may differ significantly from theseforward-looking statements due to various factors.
Information about pharmaceutical products or medical devices (including products currently
in development) included in this press release is not intended to constitute anadvertisement or medical advice.
#######

2/2